bullish
CHMP Meeting Update April 2025: Sixteen New Medicines Recommended For Approval
362 Views27 Apr 2025 10:30
Among the new medicines, Vertex’s triple combination CF drug Alyftrek, Amgen’s Thyroid eye disease drug Tepezza, and Jazz Pharmaceutical’s cancer drug Ziihera have potential to become blockbusters.
What is covered in the Full Insight:
- CHMP Meeting Overview
- New Drug Approvals
- Biosimilar Approvals
- Failed Authorizations and Withdrawals
- Extensions of Therapeutic Indications
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
x